Johnson & Johnson's Rybrevant Approved by FDA as Second-Line Treatment for EGFR-Mutated Advanced Lung Cancer

Sep 20, 2024, 12:12 PM

Johnson & Johnson's Rybrevant (amivantamab-vmjw) plus standard of care has received FDA approval for use as a second-line treatment for EGFR-mutated advanced lung cancer (NSCLC). This approval marks a significant milestone in oncology as it is the first targeted regimen to reduce the risk of disease progression by more than half. Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.